Research programme: T cell engagers - BigHat Biosciences
Latest Information Update: 08 Jan 2024
At a glance
- Originator BigHat Biosciences
- Class Antibodies; Antineoplastics; Immunoglobulin Fc fragments; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 18 Dec 2023 T cell engager - BigHat Biosciences is available for licensing as of 18 Dec 2023. https://www.bighatbio.com/
- 18 Dec 2023 Preclinical trials in Solid tumours in USA (Parenteral) before December 2023 (BigHat Biosciences pipeline, December 2023)